RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/a-2617-2084
Correction: Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib – Which One, How and For Whom?
Erratum: Die adjuvante zielgerichtete Behandlung des frühen hormonrezeptorpositiven HER2-negativen Mammakarzinoms: Olaparib, Abemaciclib oder Ribociclib – was, wie und für wen?Authors
In the e-first version of the above-mentioned article one sentence is incorrect (first paragraph of the section “Abemaciclib”). Correct is: Randomization had to occur within 16 months after surgery. Furthermore, the last paragraph of the section should read correctly: Abemaciclib has been approved in Germany for patients with HR+/HER2− eBC and more than three involved lymph nodes or with 1–3 involved lymph nodes and a tumor size of more than 5 cm (T3 stage) or a poorly differentiated tumor (G3) [7]. This was corrected in the online version on 22.5.2025.
Publikationsverlauf
Artikel online veröffentlicht:
23. Mai 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany